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Abstract
　To determine the feasibility､ safety､ humoral immune 
response､ and biological activity of multiple intratumoral 
inject ions of Ad5CMVﾝp53､ and to characterize the 
pharmacokinetics of Ad5CMVﾝp53 in patients with advanced 
non-small cell lung cancer ﾛNSCLCﾜ｡ Fifteen patients with 
histologically confirmed NSCLC and p53 mutations were 
enrolled into this phase I trial｡ Nine patients received escalating 
dose levels of Ad5CMVﾝp53 ﾛ1×109 to 1×1011 plaque-forming 
units[PFU]ﾜ as monotherapy once every 4 weeks｡ Six patients 
were treated on a 28ﾝday schedule with Ad5CMVﾝp53 in 
combination with intravenous administration of cisplatin 
ﾛ80mg/m2 ﾜ｡ Patients were monitored for toxicity､ vector 
distribution､ antibody formation､ and tumor response｡ Fifteen 
patients received a total of 63 intratumoral injections of 
Ad5CMVﾝp53 without dose-limiting toxicity｡ The most 
common treatment-related toxicity was a transient fever｡ 
Specific p53 transgene expression was detected using reverse-
transcriptase polymerase chain reaction in biopsied tumor 
tissues throughout the period of treatment despite of the 
presence of neutralizing anti-adenovirus antibody｡ Distribution 
studies revealed that the vector was detected in the gargle and 
plasma､ but rarely in the urine｡ Thirteen of 15 patients were 
assessable for efficacy; one patient had a partial response 
ﾛsquamous cell carcinoma at the carinaﾜ､ 10 patients had stable 
disease､ with three lasting ｧ9 months､ and 2 patients had 
progressive disease｡ Multiple courses of intratumoral Ad5CMVﾝ
p53 injection alone or in combination with intravenous 
administration of cisplatin were feasible and well tolerated in 
advanced NSCLC patients､ and appeared to provide clinical 
benefit｡
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症　例 年/性 病　理 部　位 TNM 分類/病期 前治療 投与経路 投与量 回数
（岡山大学）
01 58/男 扁平上皮癌 気管分岐部 cT4Ｎ0Ｍ0 St ⅢB 化学療法
放射線療法
気管支鏡 109 PFU 14
（岡山大学）











気管支鏡 109 PFU 4
（岡山大学）
04 46/女 腺癌 左肺上葉 cT2Ｎ3Ｍ1 St Ⅳ 化学療法 CT 109 PFU＋CDDP 10
（岡山大学）






06 54/男 扁平上皮癌 左肺上葉 cT3Ｎ2Ｍ0 St ⅢB 化学療法
放射線療法
CT 109 PFU＋CDDP 2
（東北大学）
07 71/男 扁平上皮癌 右肺上葉 cT4Ｎ1Ｍ0 St ⅢB 化学療法
放射線療法
気管支鏡 1010 PFU 2
（岡山大学）
08 52/男 扁平上皮癌 右肺下葉 cT2Ｎ2Ｍ0 St ⅡB 化学療法
放射線療法
気管支鏡 1010 PFU 1
（岡山大学）





CT 1010 PFU 4
（慈恵医大）
10 51/男 腺癌 右肺下葉 cT2Ｎ2Ｍ1 St Ⅳ 化学療法 CT 1010 PFU＋CDDP 1
（東京医大）
11 51/男 腺癌 右肺上葉 cT4Ｎ3Ｍ0 St ⅢB 化学療法 CT 1010 PFU＋CDDP 2
（東京医大）
12 61/男 扁平上皮癌 右肺上葉 cT4Ｎ2Ｍ0 St ⅢB 化学療法
放射線療法
気管支鏡 1010 PFU＋CDDP 2
（岡山大学）
13 62/男 扁平上皮癌 左肺下葉 cT4Ｎ3Ｍ0 St ⅢB 化学療法
放射線療法
気管支鏡 1011 PFU 1
（東北大学）
14 70/男 扁平上皮癌 左肺上葉 cT2Ｎ2Ｍ0 St ⅢA 化学療法
放射線療法
気管支鏡 1011 PFU 4
（東京医大）































































































































Track Product として認定した．Advexin はバイオベ
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